About Immutep Limited
https://www.immutep.comImmutep Limited, a biotechnology company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases.
CEO
Marc Voigt
Compensation Summary
(Year )
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2019-11-07 | Reverse | 1:10 |
| 2019-07-15 | Forward | 1011:1000 |
ETFs Holding This Stock
Summary
Showing Top 1 of 1
Ratings Snapshot
Rating : C
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:839.08K
Value:$2.47M
BLACKROCK, INC.
Shares:580.44K
Value:$1.71M
MERIDIAN WEALTH MANAGEMENT, LLC
Shares:420.9K
Value:$1.24M
Summary
Showing Top 3 of 34
About Immutep Limited
https://www.immutep.comImmutep Limited, a biotechnology company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q4-2025 | $1.9M ▼ | $40.49M ▲ | $-39.06M ▼ | -2.06K% ▼ | $-0.27 ▼ | $-36.48M ▼ |
| Q2-2025 | $3.15M ▲ | $29.56M ▲ | $-22.38M ▼ | -710.92% ▲ | $-0.15 ▲ | $-26.39M ▼ |
| Q4-2024 | $1.73M ▼ | $25.16M ▼ | $-21.49M ▼ | -1.24K% ▼ | $-0.18 | $-22.35M ▼ |
| Q2-2024 | $2.11M ▲ | $25.24M ▲ | $-21.23M ▼ | -1.01K% ▲ | $-0.18 ▲ | $-22.2M ▼ |
| Q4-2023 | $1.82M | $20.91M | $-19.27M | -1.06K% | $-0.21 | $-19.07M |
What's going well?
The company has no debt and is earning some income from other sources, which helps soften the blow of operating losses. Share dilution is not an issue.
What's concerning?
Revenue is falling fast while expenses are rising, leading to much bigger losses. The company is spending far more than it earns, and margins are getting worse.
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q4-2025 | $129.69M ▼ | $156.98M ▼ | $13.35M ▲ | $143.64M ▼ |
| Q2-2025 | $159.26M ▼ | $182.33M ▼ | $9.86M ▼ | $172.47M ▼ |
| Q4-2024 | $181.88M ▲ | $201.58M ▲ | $12.06M ▲ | $189.52M ▲ |
| Q2-2024 | $103.73M ▼ | $123.79M ▼ | $8.15M ▼ | $115.64M ▼ |
| Q4-2023 | $123.42M | $147.45M | $10.98M | $136.47M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q4-2025 | $-39.06M ▼ | $-33.5M ▼ | $24.28M ▲ | $-97.95K ▼ | $-73.89M ▼ | $-33.54M ▼ |
| Q2-2025 | $-22.38M ▼ | $-28.55M ▼ | $-30.41M ▼ | $-54.17K ▼ | $-46.46M ▼ | $-28.56M ▼ |
| Q4-2024 | $-21.49M ▼ | $-7.49M ▲ | $-20.03M ▼ | $95.66M ▲ | $66.38M ▲ | $-17.88M |
| Q2-2024 | $-21.36M ▼ | $-17.41M ▲ | $-81.12K ▼ | $-71.86K ▼ | $-6.41M ▼ | $-17.88M ▲ |
| Q4-2023 | $-19.95M | $-17.94M | $-15.5K | $38.02M | $68.22M | $-17.96M |
CEO
Marc Voigt
Compensation Summary
(Year )
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2019-11-07 | Reverse | 1:10 |
| 2019-07-15 | Forward | 1011:1000 |
ETFs Holding This Stock
Summary
Showing Top 1 of 1
Ratings Snapshot
Rating : C
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:839.08K
Value:$2.47M
BLACKROCK, INC.
Shares:580.44K
Value:$1.71M
MERIDIAN WEALTH MANAGEMENT, LLC
Shares:420.9K
Value:$1.24M
Summary
Showing Top 3 of 34